3.15
price down icon2.17%   -0.07
after-market 시간 외 거래: 3.14 -0.010 -0.32%
loading
전일 마감가:
$3.22
열려 있는:
$3.21
하루 거래량:
69,015
Relative Volume:
0.46
시가총액:
$85.22M
수익:
$1.04M
순이익/손실:
$-32.07M
주가수익비율:
-0.4884
EPS:
-6.4491
순현금흐름:
$-26.12M
1주 성능:
+3.28%
1개월 성능:
+4.65%
6개월 성능:
-30.00%
1년 성능:
-5.97%
1일 변동 폭
Value
$3.14
$3.25
1주일 범위
Value
$3.02
$3.26
52주 변동 폭
Value
$2.4501
$5.86

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
명칭
Vistagen Therapeutics Inc
Name
전화
650-577-3600
Name
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
직원
41
Name
트위터
@vistagen
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
VTGN's Discussions on Twitter

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-07-22 다운그레이드 Jefferies Buy → Hold
2022-07-22 다운그레이드 Robert W. Baird Outperform → Neutral
2022-07-22 다운그레이드 William Blair Outperform → Mkt Perform
2021-05-20 개시 Robert W. Baird Outperform
2021-02-18 개시 Jefferies Buy
2021-01-04 업그레이드 William Blair Mkt Perform → Outperform
2018-06-27 개시 Maxim Group Buy
2018-02-08 재확인 Chardan Capital Markets Buy
2017-03-28 개시 Maxim Group Buy
모두보기

Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스

pulisher
08:30 AM

Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire

08:30 AM
pulisher
Nov 02, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - Business Wire

Nov 01, 2024
pulisher
Oct 31, 2024

VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

Oct 31, 2024
pulisher
Oct 15, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha

Oct 15, 2024
pulisher
Oct 12, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

Mental Disorder Treatment Market Global Industry Forecast - openPR

Oct 11, 2024
pulisher
Oct 10, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq

Oct 10, 2024
pulisher
Oct 09, 2024

Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK

Oct 09, 2024
pulisher
Oct 09, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise

Oct 09, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 23, 2024

Vistagen advances phase 3 trial for social anxiety treatment - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - StockTitan

Sep 23, 2024
pulisher
Sep 06, 2024

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga

Sep 06, 2024
pulisher
Sep 06, 2024

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance

Sep 06, 2024
pulisher
Sep 06, 2024

Mental Disorder Treatment Market Expected to Expand at a Steady - openPR

Sep 06, 2024
pulisher
Sep 05, 2024

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Sep 05, 2024
pulisher
Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat

Sep 03, 2024
pulisher
Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World

Sep 03, 2024
pulisher
Aug 30, 2024

Mental Disorder Treatment Market Detailed In New Research - openPR

Aug 30, 2024
pulisher
Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada

Aug 28, 2024
pulisher
Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay - Investing.com

Aug 28, 2024
pulisher
Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World

Aug 24, 2024
pulisher
Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat

Aug 24, 2024
pulisher
Aug 21, 2024

The Globe and Mail - The Globe and Mail

Aug 21, 2024
pulisher
Aug 21, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

VTGN (Vistagen Therapeutics) 3-Year Revenue Growth Rate : -47.50% (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 18, 2024

VTGN (Vistagen Therapeutics) Enterprise Value : $-17.63 Mil (As of Aug. 19, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) to Post Q2 2025 Earnings of ($0.39) Per Share, William Blair Forecasts - Defense World

Aug 17, 2024
pulisher
Aug 17, 2024

VTGN (Vistagen Therapeutics) Cash-to-Debt : 54.45 (As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

Q2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN) - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript - Insider Monkey

Aug 15, 2024
pulisher
Aug 15, 2024

Vanguard Group Inc. Sells 41,346 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Aug 15, 2024
pulisher
Aug 14, 2024

Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com Canada

Aug 14, 2024
pulisher
Aug 13, 2024

VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 - InvestorPlace

Aug 13, 2024
pulisher
Aug 13, 2024

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - wallstreet:online

Aug 13, 2024
pulisher
Aug 11, 2024

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World

Aug 11, 2024
pulisher
Aug 07, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat

Aug 07, 2024
pulisher
Aug 06, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50-Day Moving Average of $3.60 - MarketBeat

Aug 06, 2024
pulisher
Aug 06, 2024

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 - businesswire.com

Aug 06, 2024
pulisher
Jul 30, 2024

Glutamate Antagonist Market Booming Worldwide With Leading Key Players -Artemis Neuroscience, VistaGen Therapeutics, Rot – Moose Gazette - Moose Gazette

Jul 30, 2024
pulisher
Jul 29, 2024

Acadian Asset Management LLC Purchases New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jul 29, 2024
pulisher
Jul 26, 2024

3 Stocks Under $15 That Could Make You a Millionaire - InvestorPlace

Jul 26, 2024
pulisher
Jul 25, 2024

Blair William & Co. IL Lowers Stock Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jul 25, 2024
pulisher
Jul 19, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.79 - Defense World

Jul 19, 2024
pulisher
Jul 19, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50-Day Moving Average of $3.79 - MarketBeat

Jul 19, 2024

Vistagen Therapeutics Inc (VTGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):